Skip to the beginning of the images gallery

Companion Diagnostics Market – Growth Opportunities, Analysis, Forecast, Global, 2022

The Transition To Precision Medicine Is Propelling The Adoption Of Cdx Platforms.,Cdx Companion Diagnostics,Companion Diagnostics Market,Companion Diagnostics Oncology

INDUSTRY
Healthcare

RELEASE DATE
13-Dec-2022

REGION
Global

DELIVERABLE TYPE
Technology Research

RESEARCH CODE
DA87-01-00-00-00

SKU
HC03611-GL-TR_27252

Companion Diagnostics (CDx): Technology Innovation and Growth Opportunities
Published on: 13-Dec-2022 | SKU: HC03611-GL-TR_27252

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink

Link1 sample $0.00

Qty

Request Sample

Need more details?

Description

The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiological effects. CDx help medical professionals make better drug therapy choices for patients.
A CDx assay is an IVD device that provides information regarding the safety, efficacy, and monitoring of a particular therapeutic product for a patient.
A CDx assay combines with a drug to form a drug-diagnostic co-development model. A strong biomarker correlation is responsible for this model's success that preclinical research deduces. A CDx assay undergoes analytical and clinical validation and is useful only if it successfully discriminates between a responder and a non-responder.
This Frost & Sullivan study discusses recent trends in CDx developments and their impact on bolstering precision medicine. The study also analyzes upcoming innovation across nucleic acid-based tests, immunoassays, molecular imaging techniques, and multimodal diagnostics. Furthermore, it explores developments in liquid biopsies, next-generation sequencing (NGS) platforms, fluorescence in-situ hybridization (FISH) techniques, and other genetic analysis tools that aid the discovery and development of novel biomarkers for new CDx products and services. The study also discusses global regulatory aspects and the need to streamline policies for accelerated government approvals.
Key Questions the Study Answers:
How are CDx and therapies co-developed?
What are the regulatory requirements for CDx development?
What are the key partnership and funding trends for CDx technologies?
What are the emerging innovations in CDx technologies?

Table of Contents

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Companion Diagnostics (CDx) Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Research Methodology

Growth Opportunity Analysis

Introduction to CDx

Role of CDx in Precision Medicine

Scope

Segmentation

Growth Drivers

Growth Restraints

Innovation Ecosystem: Overview of CDx and Therapeutics Co-development

CDx and Therapeutics Co-development

CDx and Therapeutics Co-development (continued)

Regulatory Requirements for CDx

Regulatory Requirements for CDx (continued)

Summary of Strategic Pharma and Diagnostic Collaborations

Summary of Strategic Pharma and Diagnostic Collaborations (continued)

Overview of Funding Trends

Technology Snapshot: Advances in Tissue CDx Technologies

Overview of Tissue CDx Technologies

Workflow Summary for Using AI in Digital Pathology

US FDA-approved Tissue CDx Applications in Oncology

Emerging CDx Applications in Oncology

CDx Application Landscape for Non-cancer Indications

Emerging Trends for Tissue CDx Use in Non-cancer Indications

Outlook for Tissue CDx Platforms

Technology Snapshot: Advances in Liquid Biopsy Platforms

Overview of Liquid Biopsy Platforms

Overview of Liquid Biopsy Analytes and Isolation Technologies

Comparative Analysis of Tissue and Liquid Biopsies

Snapshot of Liquid Biopsy Applications in Cancer Treatment

Key Biomarkers for Top 3 US FDA-approved Liquid Biopsy Indications

Emerging Clinical Trial Landscape for Liquid Biopsy Platforms

Snapshot of Liquid Biopsy Clinical Trials

Outlook for Liquid Biopsy Platforms

Technology Snapshot: Advances in Imaging-based CDx

Components of Imaging-based CDx

Advantages of Using Imaging-based CDx

Summary of Trends Driving the Growth of Imaging-based CDx

Small Molecules used for Molecular Imaging-based CDx

Peptides Used for Molecular Imaging-based CDx

Antibodies for Molecular Imaging-based CDx

Emerging Clinical Trial Landscape for Imaging-based CDx

Overview of Imaging-based CDx for Non-oncological Indications

Outlook for Imaging-based CDx Platforms

Analyst Perspectives

Growth Opportunity Universe

Growth Opportunity 1: Tissue Multiplexing and Digital Pathology

Growth Opportunity 1: Tissue Multiplexing and Digital Pathology (continued)

Growth Opportunity 2: NGS-based Liquid Biopsy

Growth Opportunity 2: NGS-based Liquid Biopsy (continued)

Growth Opportunity 3: Hybrid Imaging-based CDx

Growth Opportunity 3: Hybrid Imaging-based CDx (continued)

Next Steps

Your Next Steps

Why Frost, Why Now?

Legal Disclaimer

Request Sample

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

15 Sep 2026 | Global | Market Research

Vendor Profiles: Advanced Wound Care Management Market, Global, 2025

The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...

Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026

Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...

Synthetic Antibodies and AI-Optimized Immunotherapies

Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...

Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

Report download
Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:

Strategic Imperatives
Growth Opportunities
Best Practices
Companies to Action

Impacting your company's future growth potential.

Details

The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiological effects. CDx help medical professionals make better drug therapy choices for patients. A CDx assay is an IVD device that provides information regarding the safety, efficacy, and monitoring of a particular therapeutic product for a patient. A CDx assay combines with a drug to form a drug-diagnostic co-development model. A strong biomarker correlation is responsible for this model's success that preclinical research deduces. A CDx assay undergoes analytical and clinical validation and is useful only if it successfully discriminates between a responder and a non-responder. This Frost & Sullivan study discusses recent trends in CDx developments and their impact on bolstering precision medicine. The study also analyzes upcoming innovation across nucleic acid-based tests, immunoassays, molecular imaging techniques, and multimodal diagnostics. Furthermore, it explores developments in liquid biopsies, next-generation sequencing (NGS) platforms, fluorescence in-situ hybridization (FISH) techniques, and other genetic analysis tools that aid the discovery and development of novel biomarkers for new CDx products and services. The study also discusses global regulatory aspects and the need to streamline policies for accelerated government approvals. Key Questions the Study Answers: How are CDx and therapies co-developed What are the regulatory requirements for CDx development What are the key partnership and funding trends for CDx technologies What are the emerging innovations in CDx technologies

More Information

More Information
New Title	Companion Diagnostics Market – Growth Opportunities, Analysis, Forecast, Global, 2022
New Subtitle	The Transition To Precision Medicine Is Propelling The Adoption Of Cdx Platforms.,Cdx Companion Diagnostics,Companion Diagnostics Market,Companion Diagnostics Oncology
Deliverable Type	Technology Research
Author	Swati Mishra
Industries	Healthcare
No Index	No
Is Prebook	No
Keyword 1	CDX Companion Diagnostics
Keyword 2	Companion Diagnostics Market
Keyword 3	Companion Diagnostics Oncology
Podcast	No
WIP Number	DA87-01-00-00-00

Companion Diagnostics (CDx): Technology Innovation and Growth Opportunities